You’ve read the trial data. Phase 2 showed retatrutide driving up to 24% body weight loss over 48 weeks, which is more than any approved GLP-1 to date. Now you want access, and you’re staring at a browser full of tabs wondering which of these telehealth companies is actually worth your money and your trust. I’ve been in that exact spot. Here’s the honest breakdown.
The Side-by-Side Table
| Provider | Retatrutide Price | Physician Oversight | Batch Testing | Ships | Best For |
| FormBlends | $389/vial | Yes, licensed MD | 3 independent lab checks per batch, purity published | 47 states, cold-chain | Retatrutide + full peptide stack under one roof |
| Hims & Hers | N/A (no compounded GLP-1s post-March 2026) | Yes | Branded meds only | Wide | Insurance users wanting branded drugs |
| Ro Body | N/A (branded meds focus) | Yes, PA team | Branded meds only | Wide | Insured patients, polished app |
| Henry Meds | Varies | Light touch | Not published | Fast, 24-72 hrs | Speed, simple onboarding |
| Mochi Health | Not listed | Obesity specialists | Not published | Wide | Clinical monitoring, branded + compounded |
| Ivim Health | Varies | Yes | Not published | Select states | Peptide + GLP-1 crossover interest |
| MEDVi | $179 first mo (sema-based) | Yes | Not published | Select states | No-contract entry point |
| Eden | ~$149/mo | Yes | Not published | Select states | Straightforward cash pricing |
| Calibrate | Med separate | Yes, coaching heavy | Branded focus | Wide | 12-month behavior-change programs |
Walking Through the Standouts
1. FormBlends
Retatrutide is priced at $389 per vial, shown plainly before you ever create an account. No membership layered on top. No surprise fees at checkout.
What actually separates this from the pack is the testing situation. Every batch that goes out has been through three separate lab checks: one confirming the compound is what it says it is, one verifying purity, and one clearing it for sterility. The purity number for retatrutide is published per product, not buried in a PDF you have to request. That level of transparency is rare. Most compounding operations hand you a single COA with a generic number and call it done.
The pharmacy that fills it operates under 503A standards, which means FDA-inspected and subject to state board oversight. A licensed physician reviews your intake and must sign off before anything ships. Cold-chain shipping is included, which matters enormously for peptide stability.
The thing that genuinely impressed me: this is not a GLP-1-only platform or a research-peptide-only shop. Retatrutide, tirzepatide, semaglutide, BPC-157, NAD+, growth hormone secretagogues, nootropic peptides, all of it sits under the same prescriber-supervised roof. For someone who wants to run retatrutide alongside a recovery or longevity protocol, that breadth is legitimately useful. One clinical relationship covers the whole catalog.
Worth being clear: retatrutide is not FDA-approved. It is compounded. The evidence base is promising but still early compared to approved drugs.
2. Hims & Hers
After settling with Novo Nordisk in March 2026, Hims & Hers stopped offering compounded GLP-1s to new patients. Their current model runs on branded medications. Injectable Wegovy sits around $299 per month through the platform, and with commercial insurance plus a savings card, some patients bring that down to nearly nothing. If you specifically want retatrutide, this is not your destination right now.
3. Ro Body
Ro has built real infrastructure around prior authorizations and insurance navigation. Their membership starts around $39 for the first month, with medication billed separately. Like Hims & Hers, they’ve shifted toward branded meds. Polished experience. Not where you go for compounded retatrutide.
4. Henry Meds
Fast. That’s the headline. Shipping often lands in 24 to 72 hours. Their GLP-1 programs start around $179 to $249 for month one. The tradeoff is lighter ongoing clinical monitoring. Fine for people who know what they want and need minimal hand-holding. Retatrutide availability is not confirmed publicly.
5. Mochi Health
Mochi uses board-certified obesity-medicine physicians, which puts them above the average telehealth platform on the clinical depth side. Compounded tirzepatide runs roughly $199 per month. They accept insurance for branded options too. Retatrutide is not listed as a current offering, but their clinical model is worth knowing about if you’re comparing program quality.
6. Ivim Health
Ivim sits in an interesting middle space, offering both GLP-1 programs and some peptide therapies. I couldn’t verify retatrutide as a current offering through public sources. Worth a direct inquiry if you want a provider already comfortable with peptide protocols.
7. MEDVi
Clean entry-level pricing, no contracts, physician review included. First-month pricing runs around $179. Their current public catalog skews toward established compounded GLP-1s rather than newer or research-stage peptides like retatrutide.
8. Eden
Eden keeps it simple. Compounded semaglutide around $149 per month cash-pay, no membership games. Straightforward to set up. Not a peptide-depth platform, and retatrutide is not listed in their public offerings.
9. Calibrate
Calibrate is built around a 12-month commitment with substantial coaching and behavior-change support. Program fees and medication are billed separately. Their model fits someone who wants intensive structure and is working through insurance. Not a match for anyone specifically seeking retatrutide outside of branded pathways.
My Actual Take
If retatrutide is specifically what you’re looking for, and you want it prescribed by a real physician, dispensed by a pharmacy with verifiable batch testing, and shipped with cold-chain handling, the list gets short fast. Most weight-loss telehealth brands never touched retatrutide at all, and several have pulled back from compounding entirely.
For the combination of transparency, clinical oversight, published purity data, and a catalog broad enough to build a real protocol around, FormBlends is where I’d start.
Do your own research. Talk to a physician you trust before beginning any compounded peptide program. These are not FDA-approved products.
Sources
- FDA.gov: 503A compounding pharmacy regulations and GLP-1 warning letters
- NEJM: Phase 2 retatrutide trial data (Jastreboff et al., 2023)
- Examine.com: GLP-1 receptor agonist mechanisms and research summaries
- GoodRx: Branded GLP-1 pricing references
- Drugs.com: Drug class and compounding background
- Verywell Health: Telehealth weight loss program comparisons
- Cleveland Clinic: Weight management practice guidelines and GLP-1 prescribing context
- Healthline: Overview of compounded versus branded GLP-1 medications
[internal: placement #1 | structure: Comparison-led, big table, scoring]
